Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 7/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 7/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 6/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 5/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 5/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14782157 | 0.79 | NAPRT (0.41) | NAPRTSIRT6DGAT1P4HA1P4HTM | |
| SCHEMBL63857 | 0.79 | NAPRT (0.58) | NAPRTJUNNFKB1NFKB2RELA | |
| SCHEMBL31497513 | 0.77 | HDAC1 (0.56) | NAPRTSIRT6P4HA1P4HTMSMN1; SMN2 | |
| SCHEMBL1968189 | 0.77 | NNMT (0.50) | NAPRTJUNNFKB1NFKB2RELA | |
| SCHEMBL20396058 | 0.77 | NAPRT (0.40) | NAPRTSIRT6DGAT1P4HA1P4HTM | |
| SCHEMBL600134 | 0.77 | NAPRT (0.40) | NAPRTJUNNFKB1NFKB2RELA | |
| SCHEMBL4123825 | 0.77 | NAPRT (0.40) | NAPRTDGAT1P4HA1P4HTMRAB9A | |
| SCHEMBL17801 | 0.75 | NAPRT (0.72) | NAPRTKCNQ3KCNQ2KCNE1KCNQ1 | |
| Hydrochloric Acid SCHEMBL4040974 | 0.75 | HDAC1 (0.54) | NAPRTSIRT6P4HA1P4HTMSMN1; SMN2 | |
| SCHEMBL29760376 | 0.75 | NAPRT (0.72) | NAPRTKCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122865-A1 | BIFUNCTIONAL ABL1-BINDING COMPOUNDS AND USES THEREOF | PHOTYS THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085738-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025081082-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-119684814-A | Yellow dichromatic dye and application thereof | 烟台海森大数据有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| US-20240279216-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-08-22 | — | — | US | disclosed |
| EP-4353720-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2024-04-17 | — | — | EP | disclosed |
| CN-117396471-A | Novel piperidine derivatives and pharmaceutical compositions for inhibiting autotaxin comprising the same | 株式会社次代生物科学 | 2024-01-12 | — | — | CN | disclosed |
| CN-1196685-C | Pyrimidine derivatives | ASTRAZENCA AB (SE) | 2005-04-13 | — | — | CN | disclosed |
| CN-1541208-A | 2-phenylamino-pyrimidine derivatives as cyclin dependent kinase inhibitors | — | 2004-10-27 | — | — | CN | disclosed |
| EP-1361879-A1 | 2,4-DISUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-19 | — | — | EP | disclosed |
| CN-1454210-A | Pyrimidine derivatives | ASTRAZENCA AB (SE) | 2003-11-05 | — | — | CN | disclosed |
| US-20020183335-A1 | Administering disubstituted pyrimidine-5-carboxamide derivatives for therapy of disorders responsive to the modulation of the potassium channels | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-05 | — | — | US | disclosed |
| WO-2002066036-A1 | 2,4-DISUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
| US-5935966-A | COMPOUNDS THAT BLOCK THE ACTIVATION OF TRANSCRIPTION FACTORS THROUGH INHIBITION OF A FAMILY OF SPECIFIC KINASES, DECREASING PROINFLAMMATORY PROTEINS TO TREAT AUTOIMMUNE DISEASES AND AS GENERAL ANTIINFLAMMATORY AGENTS | SIGNAL PHARMACEUTICALS, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5852028-A | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1998038171-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997009325-A1 | PYRIMIDINE CARBOXYLATES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279216-A1 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | ENPP2, UACA, ITCH | NAPRT 955/4885JUN 3937/4885NFKB1 797/4885 |
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | NAPRT 2760/4885JUN 2441/4885NFKB1 1418/4885 |
| US-20020183335-A1 | Administering disubstituted pyrimidine-5-carboxamide derivatives for therapy of disorders responsive to the modulation of the potassium channels | KCNQ5, KCNQ1, KCNQ2 | NAPRT 1457/4885JUN 3580/4885NFKB1 1080/4885 |
| US-12145929-B2 | Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same | ENPP2, UACA, ACAT2 | NAPRT 988/4885JUN 3843/4885NFKB1 963/4885 |
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | NAPRT 3830/4885JUN 4270/4885NFKB1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.